AOD-9604 comes up often in conversation and rarely with the context attached. Here we lay out the basics in order, then work through the practical considerations.
Last reviewed on 2026-03-27. Where a claim depends on a specific study, the study is described rather than over-claimed.
AOD9604 is commonly supplied as a white to off-white lyophilized powder. The powder is typically stored at -20 °C or below, protected from light and moisture, because peptides can degrade through oxidation, hydrolysis, or aggregation. If it is reconstituted for laboratory use, an appropriate aqueous buffer or solvent is chosen, and the solution is kept cold and handled to avoid repeated freeze-thaw cycles. These practices support stability but do not imply suitability for human use.
Identity and purity are usually assessed with reversed-phase high-performance liquid chromatography and mass spectrometry. Reversed-phase HPLC separates the peptide from related impurities and can estimate purity by ultraviolet absorbance, while mass spectrometry confirms the molecular mass and detects modifications. Peptide mapping, amino acid analysis, and disulfide mapping may be used when the sequence or disulfide arrangement must be verified. Because AOD9604 contains cysteine residues, oxidation and disulfide isomers are possible quality concerns in synthetic batches.
AOD-9604 is a synthetic peptide whose structure corresponds to a C-terminal segment of human growth hormone. It is often described as hGH fragment 176-191, a 16-amino-acid sequence. The peptide was designed to isolate a region of hGH associated with fat metabolism while avoiding the full hormone's growth-promoting actions. Laboratory and commercial materials typically present it as a lyophilized powder for research use. Its identity is defined by amino acid sequence, not by a single brand.
The fragment includes residues that can form an internal disulfide bond between two cysteine positions. This structural feature can influence how the peptide folds and how stable it is in solution. AOD-9604 differs from full-length hGH in size and receptor interactions; it does not contain the entire growth hormone sequence. Published descriptions sometimes use slightly different residue numbering, so sequence information should be checked against primary sources. The molecule is small compared with intact hGH, which affects analytical detection and purification approaches.
Interest in AOD-9604 arose from attempts to separate metabolic effects from growth effects attributed to hGH. Early work explored whether the fragment could influence lipolysis or fat oxidation without promoting growth. Those questions remain partly unresolved because human data are limited and results have varied across studies. The peptide is not a hormone replacement for hGH and is not equivalent to hGH in clinical use. Its research history includes both laboratory studies and commercial marketing claims that are not the same as regulatory approval.
| Property | Value | Notes |
|---|---|---|
| Appearance | White to off-white powder | Lyophilized form; visual inspection |
| Solubility | Soluble in water and aqueous buffers | Depends on pH, purity, and counterion |
| Typical storage | -20 °C or below, desiccated | Protect from light; avoid repeated freeze-thaw after reconstitution |
| Common analytical method | Reversed-phase HPLC and mass spectrometry | Purity by HPLC; identity and mass by LC-MS or MALDI-TOF |
| Common synonyms | hGH fragment 176–191; AOD-9604 | Names vary in research and product labeling |
Proposed mechanisms for AOD-9604 focus on fat cells. Laboratory studies suggest the peptide can increase lipolysis, the breakdown of stored fat, and reduce lipogenesis, the formation of new fat. Unlike full human growth hormone, it does not appear to stimulate substantial IGF-1 production in the studies reported so far. Some evidence points to beta-adrenergic signaling, but the precise receptor targets and downstream pathways remain unresolved. The fragment is not thought to act through the classical growth hormone receptor.
Clinical development of AOD-9604 included trials in people with obesity. Reports from early-phase and mid-phase studies described modest or inconsistent changes in body weight. A phase IIb program did not meet its primary endpoint, and the compound was not approved for medical use. Differences in formulation, delivery route, and participant characteristics may explain some of the variation. Later investigations explored whether the peptide might have effects in other tissues, including cartilage.
AOD-9604 has been investigated primarily as a potential treatment for obesity and related metabolic conditions. Early laboratory work examined its effects on fat cells, and later studies moved into animal models and human clinical trials. Some trials reportedly reached Phase II, but the program did not lead to an approved medicine. Published summaries often note that weight-loss results were modest or inconsistent. The full trial data are not all publicly available in detail.
Regulatory treatment of AOD-9604 has varied. In sports anti-doping, the peptide became widely discussed during a 2013 investigation into an Australian professional sports club. Authorities at the time debated whether it fell under prohibitions on growth hormone and related substances. Later clarifications and updated lists have addressed the compound in different ways. Anyone seeking current status should consult the latest applicable rules, and commercial supply for human use is not authorized in major markets.
And you do not set 2,000 tanks and 20,000 men in motion within 48 hours." On 31 August 2008, Matthew Bryza stated at Bled Strategic Forum in Slovenia that the United States had actively been working to prevent Georgia from responding to South Ossetian attacks. In August 2008, Vadim Kozaev, employee of Ministry of Internal Affairs of North Ossetia–Alania, and his brother Vladislav Kozaev, hero of Abkhazia and South Ossetia, alleged that Eduard Kokoity, the president of South Ossetia, knew in advance that the war was coming and fled Tskhinvali.
The prognosis is worse in those with larger burns, those who are older, and females. The presence of a smoke inhalation injury, other significant injuries such as long bone fractures, and serious co-morbidities (e.g. heart disease, diabetes, psychiatric illness, and suicidal intent) also influence prognosis. On average, of those admitted to burn centers in the United States, 4% die, with the outcome for individuals dependent on the extent of the burn injury. For example, admittees with burn areas less than 10% TBSA had a mortality rate of less than 1%, while admittees with over 90% TBSA had a mortality rate of 85%. In Afghanistan, people with more than 60% TBSA burns rarely survive. The Baux score has historically been used to determine prognosis of major burns. However, with improved care, it is no longer very accurate. The score is determined by adding the size of the burn (% TBSA) to the age of the person and taking that to be more or less equal to the risk of death. Burns in 2013 resulted in 1.2 million years lived with disability and 12.3 million disability adjusted life years.
In 1993, the FDA issued a document for the content limits of DON in food and animal feed at an advisory level. In 2003, US published a patent that is very promising for farmers to produce a trichothecene-resistant crop. Zearalenone Zearalenols
Sources: en.wikipedia.org
== Ligands == Activators C8 (NAMPT activator) JGB-1-155 (positive allosteric modulator) Myricanol P7C3 SBI-797812 Inhibitors A-1293201 CHS-828 Daporinad (FK866/APO866) GNE-617 Padnarsertib (KPT-9274) STF-118804
=== Literature === In Western literature, vegetarianism, and topics that relate to it, have informed a "gamut of literary genres", whether literary fiction or those fictions focusing on utopias, dystopias, or apocalypses, with authors shaped by questions about human identity and "our relation to the environment", implicating vegetarianism and veganism. Others have pointed to the lack of "memorable characters" who are vegetarian. There are also vegetarian themes in horror fiction, science fiction and poetry. In 1818, Mary Shelley published the novel Frankenstein. Writer and animal rights advocate Carol J. Adams argued in her seminal book, The Sexual Politics of Meat that the unnamed creature in the novel was a vegetarian. She argued that the book was "indebted to the vegetarian climate" of its day and that vegetarianism is a major theme in the novel as a whole. She notes that the creature gives an "emotional speech" talking about its dietary principles, which makes it a "more sympathetic being" than others. She also said that it connected with Vegetarianism in the Romantic Era who believed that the Garden of Eden was meatless, rewrote the myth of Prometheus, the ideas of Jean-Jacques Rousseau, and feminist symbolism. Adams concludes that it is more likely that the "vegetarian revelations" in the novel are "silenced" due to the lack of a "framework into which we can assimilate them." Apart from Adams, scholar Suzanne Samples pointed to "gendered spaces of eating and consumption" within Victorian England which influenced literary characters of the time.
== Concentration and state in cells == In rat liver, the total amount of NAD+ and NADH is approximately 1 μmole per gram of wet weight, about 10 times the concentration of NADP+ and NADPH in the same cells. The actual concentration of NAD+ in cell cytosol is harder to measure, with recent estimates in animal cells ranging around 0.3 mM, and approximately 1.0 to 2.0 mM in yeast. However, more than 80% of NADH fluorescence in mitochondria is from bound form, so the concentration in solution is much lower. NAD+ concentrations are highest in the mitochondria, constituting 40% to 70% of the total cellular NAD+. NAD+ in the cytosol is carried into the mitochondrion by a specific membrane transport protein, since the coenzyme cannot diffuse across membranes. The intracellular half-life of NAD+ was claimed to be between 1–2 hours by one review, whereas another review gave varying estimates based on compartment: intracellular 1–4 hours, cytoplasmic 2 hours, and mitochondrial 4–6 hours. The balance between the oxidized and reduced forms of nicotinamide adenine dinucleotide is called the NAD+/NADH ratio. This ratio is an important component of what is called the redox state of a cell, a measurement that reflects both the metabolic activities and the health of cells. The effects of the NAD+/NADH ratio are complex, controlling the activity of several key enzymes, including glyceraldehyde 3-phosphate dehydrogenase and pyruvate dehydrogenase.
Sources: en.wikipedia.org
Pennyroyal is toxic to humans and has differing effects dependent on the volume and concentration ingested. The most concentrated and toxic form of the pennyroyal plant is pennyroyal oil. The oil contains pulegone (a cyclohexanone), the molecule found in the highest concentration (80-92%) in the pennyroyal plant. Pulegone causes a variety of ailments in those who ingest it and is what causes the plant to have its peppermint flavor. Symptoms that may persist after ingesting a small dose (<10 mL) of pennyroyal oil are nausea, vomiting, abdominal pain and dizziness. Larger volumes may result in multiorgan failure that could lead to death. There are no current toxicokinetics studies performed on humans for the effects of pulegone, but there are some studies performed on other mammals. When pulegone is ingested, it is broken down by the liver and reacts to form multiple toxic metabolites that can wreak havoc in the body. Some identified metabolites are menthofuran, piperitenone, piperitone, and menthone. As little as 10 mL of pennyroyal oil ingestion was associated with moderate to severe hepatic toxicity.
== Content == The Code contains both mandatory regulations and recommended provisions, setting out the minimum stability standards for ships. This includes information on precautions against capsizing, metacentric heights (GM), righting levers (GZ), rolling criteria, Free surface effect and watertight integrity. The 2008 version of the Code details guidelines on Second Generation Intact Stability for ships, specifically criteria for dynamic stability and damage assessment. The Code is split into two parts. Part A contains mandatory criteria. Part B contains additional guidelines and recommendations. The Code requires each ship to have a stability book on the ship. For passenger ships, a regular survey is required.
=== Designed proteins === Numerous protein structures are the result of rational design and do not exist in nature. Proteins can be designed from scratch (de novo design) or by making calculated variations on a known protein structure and its sequence (known as protein redesign). Rational protein design approaches make protein-sequence predictions that will fold to specific structures. These predicted sequences can then be validated experimentally through methods such as peptide synthesis, site-directed mutagenesis, or Artificial gene synthesis.
Sources: en.wikipedia.org
Lyophilized AOD9604 is generally kept at -20 °C or colder, desiccated, and protected from light. Reconstituted solutions are usually refrigerated and handled to minimize repeated freeze-thaw cycles. These are general laboratory handling practices, not instructions for human use.
Mass spectrometry, such as LC-MS or MALDI-TOF, confirms the molecular mass and can reveal sequence-related impurities. Reversed-phase HPLC is used for purity, and peptide mapping or amino acid analysis can support sequence identity. No single method establishes every quality attribute.
No. AOD9604 is a short synthetic fragment of the hGH sequence, not the full 191-amino-acid hormone. It lacks the regions that mediate hGH receptor activation and growth-promoting effects. Products labeled as AOD9604 should not be assumed to have the same properties as hGH.
It is a synthetic peptide based on a C-terminal fragment of human growth hormone. It is commonly referred to as hGH fragment 176-191 and is studied for metabolic effects rather than growth effects.